Your browser doesn't support javascript.
loading
The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies.
Goll, Johannes B; Bosinger, Steven E; Jensen, Travis L; Walum, Hasse; Grimes, Tyler; Tharp, Gregory K; Natrajan, Muktha S; Blazevic, Azra; Head, Richard D; Gelber, Casey E; Steenbergen, Kristen J; Patel, Nirav B; Sanz, Patrick; Rouphael, Nadine G; Anderson, Evan J; Mulligan, Mark J; Hoft, Daniel F.
Afiliação
  • Goll JB; Department of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, United States.
  • Bosinger SE; Division of Microbiology & Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, United States.
  • Jensen TL; Department of Pathology & Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA, United States.
  • Walum H; Emory NPRC Genomics Core, Emory National Primate Research Center, Emory University, Atlanta, GA, United States.
  • Grimes T; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
  • Tharp GK; Department of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, United States.
  • Natrajan MS; Division of Microbiology & Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, United States.
  • Blazevic A; Department of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, United States.
  • Head RD; Emory NPRC Genomics Core, Emory National Primate Research Center, Emory University, Atlanta, GA, United States.
  • Gelber CE; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, United States.
  • Steenbergen KJ; Hope Clinic of the Emory Vaccine Center, Emory University, Atlanta, GA, United States.
  • Patel NB; Division of Infectious Diseases, Allergy, and Immunology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, United States.
  • Sanz P; McDonnell Genome Institute, Washington University, St. Louis, MO, United States.
  • Rouphael NG; Department of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, United States.
  • Anderson EJ; Department of Biomedical Data Science and Bioinformatics, The Emmes Company, LLC, Rockville, MD, United States.
  • Mulligan MJ; Emory NPRC Genomics Core, Emory National Primate Research Center, Emory University, Atlanta, GA, United States.
  • Hoft DF; Office of Biodefense, Research Resources and Translational Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.
Front Immunol ; 13: 1093242, 2022.
Article em En | MEDLINE | ID: mdl-36741404
ABSTRACT

Introduction:

Over the last decade, the field of systems vaccinology has emerged, in which high throughput transcriptomics and other omics assays are used to probe changes of the innate and adaptive immune system in response to vaccination. The goal of this study was to benchmark key technical and analytical parameters of RNA sequencing (RNA-seq) in the context of a multi-site, double-blind randomized vaccine clinical trial.

Methods:

We collected longitudinal peripheral blood mononuclear cell (PBMC) samples from 10 subjects before and after vaccination with a live attenuated Francisella tularensis vaccine and performed RNA-Seq at two different sites using aliquots from the same sample to generate two replicate datasets (5 time points for 50 samples each). We evaluated the impact of (i) filtering lowly-expressed genes, (ii) using external RNA controls, (iii) fold change and false discovery rate (FDR) filtering, (iv) read length, and (v) sequencing depth on differential expressed genes (DEGs) concordance between replicate datasets. Using synthetic mRNA spike-ins, we developed a method for empirically establishing minimal read-count thresholds for maintaining fold change accuracy on a per-experiment basis. We defined a reference PBMC transcriptome by pooling sequence data and established the impact of sequencing depth and gene filtering on transcriptome representation. Lastly, we modeled statistical power to detect DEGs for a range of sample sizes, effect sizes, and sequencing depths. Results and

Discussion:

Our results showed that (i) filtering lowly-expressed genes is recommended to improve fold-change accuracy and inter-site agreement, if possible guided by mRNA spike-ins (ii) read length did not have a major impact on DEG detection, (iii) applying fold-change cutoffs for DEG detection reduced inter-set agreement and should be used with caution, if at all, (iv) reduction in sequencing depth had a minimal impact on statistical power but reduced the identifiable fraction of the PBMC transcriptome, (v) after sample size, effect size (i.e. the magnitude of fold change) was the most important driver of statistical power to detect DEG. The results from this study provide RNA sequencing benchmarks and guidelines for planning future similar vaccine studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucócitos Mononucleares / Benchmarking Tipo de estudo: Clinical_trials / Guideline / Qualitative_research Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucócitos Mononucleares / Benchmarking Tipo de estudo: Clinical_trials / Guideline / Qualitative_research Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos